Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan 13:6:1446.
doi: 10.3389/fmicb.2015.01446. eCollection 2015.

High Emergence of ESBL-Producing E. coli Cystitis: Time to Get Smarter in Cyprus

Leon Cantas  1 , Kaya Suer  2 , Emrah Guler  3 , Turgut Imir  3
Affiliations

High Emergence of ESBL-Producing E. coli Cystitis: Time to Get Smarter in Cyprus

Leon Cantas et al. Front Microbiol. .

Abstract

Background: Widespread prevalence of extended-spectrum βeta-lactamase producing Escherichia coli (ESBL-producing E. coli) limits the infection therapeutic options and is a growing global health problem. In this study our aim was to investigate the antimicrobial resistance profile of the E. coli in hospitalized and out-patients in Cyprus.

Results: During the period 2010-2014, 389 strains of E. coli were isolated from urine samples of hospitalized and out-patients in Cyprus. ESBL-producing E. coli, was observed in 53% of hospitalized and 44% in out-patients, latest one being in 2014. All ESBL-producing E. coli remained susceptible to amikacin, carbapenems except ertapenem (in-patients = 6%, out-patients = 11%).

Conclusion: High emerging ESBL-producing E. coli from urine samples in hospitalized and out-patients is an extremely worrisome sign of development of untreatable infections in the near future on the island. We therefore emphasize the immediate need for establishment of optimal therapy guidelines based on the country specific surveillance programs. The need for new treatment strategies, urgent prescription habit changes and ban of over-the-counter sale of antimicrobials at each segment of healthcare services is also discussed in this research.

Keywords: Cyprus; E. coli; ESBL; UTI; antibiotic; resistance.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Percentage distribution of ESBL-producing Escherichia coli in urine samples of hospitalized patients and out-patients (2010/2011–2014).
FIGURE 2
FIGURE 2
Antibiotics susceptibility testing for all E. coli strains isolated from in-patients with cystitis (2010/2011–2014).
FIGURE 3
FIGURE 3
Antibiotics susceptibility testing for all E. coli strains isolated from out-patients with cystitis(2010/2011–2014).
See this image and copyright information in PMC

References

    1. Abedon S. T., Kuhl S. J., Blasdel B. G., Kutter E. M. (2011). Phage treatment of human infections. Bacteriophage 1 66–85. 10.4161/bact.1.2.15845 - DOI - PMC - PubMed
    1. Allocati N., Masulli M., Alexeyev M. F., Di Ilio C. (2013). Escherichia coli in Europe: an overview. Int. J. Environ. Res. Public Health 10 6235–6254. 10.3390/ijerph10126235 - DOI - PMC - PubMed
    1. Ansari S., Nepal H. P., Gautam R., Shrestha S., Neopane P., Gurung G., et al. (2015). Community acquired multi-drug resistant clinical isolates of Escherichia coli in a tertiary care center of Nepal. Antimicrob. Resist. Infect. Control 4 15 10.1186/s13756-015-0059-2 - DOI - PMC - PubMed
    1. Balode A., Punda-Polic V., Dowzicky M. J. (2013). Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004–2010. Int. J. Antimicrob. Agents 41 527–535. 10.1016/j.ijantimicag.2013.02.022 - DOI - PubMed
    1. Bikard D., Euler C., Jiang W., Nussenzweig P. M., Goldberg G. W., Duportet X., et al. (2014). Development of sequence-specific antimicrobials based on programmable CRISPR-Cas nucleases. Nat. Biotechnol. 32 1146–1150. 10.1038/nbt.3043 - DOI - PMC - PubMed

LinkOut - more resources